Literature DB >> 10965905

Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation.

L Liang1, J Jiang, S J Frank.   

Abstract

Interaction of GH with the cell-surface GH receptor (GHR) causes activation of the GHR-associated tyrosine kinase, JAK2, and consequent triggering of signaling cascades including the STAT, Ras/Raf/MEK1/MAP kinase, and insulin receptor substrate-1(IRS-1)/PI3kinase pathways. We previously showed that IRS- and GHR-deficient 32D cells that stably express the rabbit GHR and rat IRS-1 (32D-rbGHR-IRS-1) exhibited markedly enhanced GH-induced proliferation and MAP kinase (ERK1 and ERK2) activation compared with cells expressing only the GHR (32D-rbGHR). We now examine biochemical mechanism(s) by which IRS-1 augments GH-induced MAP kinase activation. Time-course experiments revealed a similarly transient (maximal at 15 min) GH-induced ERK1 and ERK2 activation in both 32D-rbGHR and 32D-rbGHR-IRS-1 cells, but, consistent with our prior findings, substantially greater activation was seen in the IRS-1-containing cells. In both cells, GH-induced MAP kinase activation was markedly blunted by the MEK1 inhibitor, PD98059, but not by the PKC inhibitor, GF109203X. Interestingly, pretreatment with the PI3K inhibitor, wortmannin (EC50 approximately 10 nM), significantly reduced GH-induced MAP kinase activation in both 32D-rbGHR and 32D-rbGHR-IRS-1 cells. This same pattern in both cells of IRS-1-dependent augmentation and IRS-1-independent wortmannin sensitivity was also observed for GH-induced activation of Akt and MEK1 (using state-specific antibody blotting for both), despite the lack of difference in GHR, JAK2, SHP-2, p85, Akt, Ras, Raf-1, MEK1, ERK1, or ERK2 abundance between the two cells. A different PI3K inhibitor, LY294002 (50 microM), substantially inhibited (roughly 72%) GH-induced MAP kinase activation in 32D-rbGHR-IRS-1 cells, but only marginally (and statistically insignificantly) inhibited GH-induced MAP kinase activation in 32D-rbGHR cells. Because GH-induced Akt activation was completely inhibited in both cells by the same concentration of LY294002, these findings indicate that the wortmannin sensitivity of both the IRS-1-independent and -dependent GH-induced MAP kinase activation may reflect the activity of another wortmannin-sensitive target(s) in addition to PI3K in mediation of GH-induced MAP kinase activation in these cells. Notably, GH-induced STAT5 tyrosine phosphorylation, unlike Akt or MAPK activation, did not differ between the cells. Finally, while GH promoted accumulation of activated Ras in both cells, both basal and GH-induced activated Ras levels were greater in cells expressing IRS-1 than in 32D-rbGHR cells. These data indicate that while GH induces tyrosine phosphorylation of STAT5 and activation of the Ras/Raf/MEK1/MAPK and PI3K pathways, IRS-1 expression augments the latter two more than the former.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965905     DOI: 10.1210/endo.141.9.7673

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Osteoblast-restricted Disruption of the Growth Hormone Receptor in Mice Results in Sexually Dimorphic Skeletal Phenotypes.

Authors:  Vandana Singhal; Brian C Goh; Mary L Bouxsein; Marie-Claude Faugere; Douglas J DiGirolamo
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling.

Authors:  Minghua Li; Zhiqin Li; David L Morris; Liangyou Rui
Journal:  Endocrinology       Date:  2007-01-04       Impact factor: 4.736

3.  Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.

Authors:  Young Seo Kim; Arum Yoo; Jeong Woo Son; Hyun Young Kim; Young-Jun Lee; Sejin Hwang; Kyu-Yong Lee; Young Joo Lee; Cenk Ayata; Hyung-Hwan Kim; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

4.  Nuclear factor-kappaB (NF-kappaB) p65 interacts with Stat5b in growth plate chondrocytes and mediates the effects of growth hormone on chondrogenesis and on the expression of insulin-like growth factor-1 and bone morphogenetic protein-2.

Authors:  Shufang Wu; Allison Morrison; Hongzhi Sun; Francesco De Luca
Journal:  J Biol Chem       Date:  2011-05-18       Impact factor: 5.157

5.  Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping.

Authors:  Jing Jiang; Yu Wan; Xiangdong Wang; Jie Xu; Jonathan M Harris; Peter E Lobie; Yu Zhang; Kurt R Zinn; Michael J Waters; Stuart J Frank
Journal:  Endocrinology       Date:  2011-10-11       Impact factor: 4.736

6.  PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium.

Authors:  Joëlle Dupont; Jean Pierre Renou; Moshe Shani; Lothar Hennighausen; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 7.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

Review 8.  Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.

Authors:  Stuart J Frank; Serge Y Fuchs
Journal:  Biochim Biophys Acta       Date:  2008-06-09

Review 9.  Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling.

Authors:  Stuart J Frank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-31       Impact factor: 2.673

10.  Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding.

Authors:  H Demaegdt; L Smitz; J-P De Backer; M T Le; M Bauwens; E Szemenyei; G Tóth; Y Michotte; P Vanderheyden; G Vauquelin
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.